“…Putting the issue of dwell time aside, the release of antibiotic moieties (i.e., rifampicin) have a long history but the increasing threat of bacterial resistance has driven considerable effort to examine alternative antimicrobial agents. Various antimicrobial peptides [100,108,[113][114][115], guanidine derivatives (i.e., poly hexamethyl biguanide, polyarginines) [103,104], quaternary ammonium compounds [96,98], nitric oxide precursors [105,106,116,117], silver [118][119][120] and a host of other small molecules/metal ions or nanoparticles [107,110,118,[121][122][123][124] with possible biocidal activity have all been investigated as potential modifiers for use in catheters and, while these invariably impact bacterial colonisation, they have yet to make the leap to commercial exploitation and/or substantive clinical trials.…”